Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19910325 | 1.00 | KCNH2 (0.53) | KCNH2TLR7CYP2D6DRD1HTR2A | |
| SCHEMBL19910213 | 0.97 | KCNH2 (0.52) | KCNH2TLR7CYP2D6DRD1HTR2A | |
| SCHEMBL16483508 | 0.97 | KCNH2 (0.52) | KCNH2TLR7CYP2D6DRD1HTR2A | |
| SCHEMBL20901241 | 0.94 | KCNH2 (0.54) | KCNH2TLR7TLR8 | |
| SCHEMBL16484026 | 0.94 | KCNH2 (0.54) | KCNH2TLR7TLR8 | |
| SCHEMBL18511625 | 0.89 | KCNH2 (0.39) | KCNH2TLR7CYP2D6DRD1HTR2A | |
| SCHEMBL19910207 | 0.87 | TLR7 (0.49) | KCNH2TLR7CYP2D6DRD1HTR2A | |
| SCHEMBL16484142 | 0.87 | TLR7 (0.49) | KCNH2TLR7CYP2D6DRD1HTR2A | |
| SCHEMBL18511630 | 0.86 | KCNH2 (0.39) | KCNH2TLR7CYP2D6DRD1HTR2A | |
| SCHEMBL18511621 | 0.83 | KCNH2 (0.41) | KCNH2TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220504-B2 | Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2022-01-11 | — | — | US | disclosed |
| US-20190330217-A1 | PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2019-10-31 | — | — | US | disclosed |
| US-10259814-B2 | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | JANSSEN SCIENCES IRELAND UC (IE) | 2019-04-16 | — | — | US | disclosed |
| EP-2906563-B1 | PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-28 | — | — | EP | disclosed |
| US-20170044169-A1 | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | JANSSEN SCIENCES IRELAND UC (IE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044169-A1 | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | JANSSEN SCIENCES IRELAND UC (IE) | 2017-02-16 | — | — | US | disclosed |
| US-9499549-B2 | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-22 | — | — | US | disclosed |
| US-9499549-B2 | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-22 | — | — | US | disclosed |
| US-20150239892-A1 | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases | JANSSEN R&D IRELAND (IE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239892-A1 | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases | JANSSEN R&D IRELAND (IE) | 2015-08-27 | — | — | US | disclosed |
| WO-2014056953-A1 | PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220504-B2 | Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases | TYMS, TYMP, DPYD | KCNH2 3492/4885TLR7 1485/4885CYP2D6 803/4885 |
| US-20150239892-A1 | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases | TYMS, TYMP, DPYD | KCNH2 3698/4885TLR7 1165/4885CYP2D6 833/4885 |
| US-20170044169-A1 | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | TYMS, TYMP, DPYD | KCNH2 3492/4885TLR7 1485/4885CYP2D6 803/4885 |
| US-10259814-B2 | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | TYMS, TYMP, DPYD | KCNH2 3492/4885TLR7 1485/4885CYP2D6 803/4885 |
| US-20190330217-A1 | PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | TYMS, TYMP, DPYD | KCNH2 3492/4885TLR7 1485/4885CYP2D6 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.